China to Cancel VAT Export Rebates on E-Cigarette Products from April 1, 2026

Regulations
Jan.10
China to Cancel VAT Export Rebates on E-Cigarette Products from April 1, 2026
China’s Ministry of Finance and State Taxation Administration have announced adjustments to export tax rebate policies, placing nicotine-containing non-combustible inhalation products within the scope of items subject to rebate cancellation. The measures will take effect from April 1, 2026.

2Firsts, January 10, 2026 — On January 9, China’s Ministry of Finance and the State Taxation Administration issued Announcement No. 2 of 2026, announcing adjustments to value-added tax (VAT) export rebate policies for certain products.

 

According to the announcement, VAT export rebates for photovoltaic and other products will be cancelled starting April 1, 2026. In the appended Product List for Photovoltaic and Other Items, product code 2404120000 — “products for inhalation without combustion, containing nicotine, not containing tobacco or reconstituted tobacco” — is included. Based on this, e-cigarette products will no longer be eligible for VAT export rebates.

 

China to Cancel VAT Export Rebates on E-Cigarette Products from April 1, 2026
Screenshot of a Ministry of Finance and State Taxation Administration Announcement

 

The announcement also adjusts VAT export rebate policies for battery products. From April 1 to December 31, 2026, the VAT export rebate rate for battery products will be reduced from 9% to 6%; from January 1, 2027, VAT export rebates for battery products will be cancelled. The relevant measures apply to products listed in the appended Battery Product List. Where e-cigarette battery packs are exported as battery products and declared separately at customs, the applicable export rebate treatment will depend on whether the declared product falls within the scope of the battery product list.

 

2Firsts will continue to monitor developments and report on the implications of the policy for relevant product exports.



Cover image generated by ChatGPT
 


2FIRSTS | BREAKING: China Brings Nicotine Pouches Under Tobacco Monopoly Regulation, Signaling Major Shift for Oral Products
2FIRSTS | BREAKING: China Brings Nicotine Pouches Under Tobacco Monopoly Regulation, Signaling Major Shift for Oral Products
China has for the first time issued clear regulatory rules for nicotine pouches and other oral nicotine products, formally classifying them under the tobacco monopoly alongside cigarettes and tobacco, ending a long-standing legal grey zone and laying the regulatory groundwork for their potential domestic launch.
www.2firsts.com
 

Philip Morris and BAT’s Nicoventures Win EPO Appeal to Revoke VMR Vape Patent
Philip Morris and BAT’s Nicoventures Win EPO Appeal to Revoke VMR Vape Patent
The EPO Technical Board of Appeal 3.2.02 (T 1319/24) revoked VMR Products LLC’s EP3613453 “VAPORIZER” patent after finding that a 2012 YouTube video of the Innokin iTaste VV (D3) disclosed the claimed electrical contact arrangement. Opponents Nicoventures Trading Ltd (BAT subsidiary) and Philip Morris Products S.A. prevailed.
BATPMI
Feb.17
Charlie’s Holdings Signs Licensing Agreement with IKE Tech to Commercialize Age-Gated Vape Technology in the U.S.
Charlie’s Holdings Signs Licensing Agreement with IKE Tech to Commercialize Age-Gated Vape Technology in the U.S.
Charlie’s Holdings has signed a licensing agreement with IKE Tech to commercialize an age-gated vape activation system in the U.S. The technology combines biometric authentication, BLE hardware, and a mobile app for continuous device-level age verification. The company plans to test-market the system with SBX nicotine analogue products this spring and may later apply it to PACHA-branded ENDS.
News
Jan.06
Japan Tax Reform Threatens JTI Heated Tobacco Growth in 2026
Japan Tax Reform Threatens JTI Heated Tobacco Growth in 2026
Japan’s plan to remove the lower tax rate for heated tobacco products could slow growth in the country’s largest HTP market, JTI’s CFO said. Retail prices may rise by 70 to 100 yen, though the company plans phased increases to soften the impact.
JTI
Feb.15
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24